About Myelodysplastic Syndrome
Myelodysplastic syndrome is a group of hematologic disorders that arise in the bone marrow and spread into the blood. The syndrome is characterized by the inability of the hematopoietic cells produced in the bone marrow to attain maturity. Cytological dysplasia is a common feature of the syndrome, progressing to acute myeloid leukemia in about 30% of individuals with myelodysplastic syndrome. The disease is age-related, mostly affecting people aged 60 and above. Smoking, exposure to radiation, contact with chemicals such as benzene, genetic mutations, and chemotherapy can cause myelodysplastic syndrome.
Technavios analysts forecast the global myelodysplastic syndrome market to grow at a CAGR of 9.93% during the period 2015-2019.
Covered in this report
The report covers the present scenario and the growth prospects of the global myelodysplastic syndrome market for 2015-2019. To calculate the market size, we consider revenue generated from the sales of various drugs used for treating myelodysplastic syndrome.
The report describes the market by region:
Americas: The US, Canada, Mexico, and Brazil
EMEA: The UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
APAC: Japan, China, Australia, Singapore, South Korea, and India
Technavios report, Global Myelodysplastic Syndrome Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
Celgene
Novartis
Otsuka
Other prominent vendors
Acceleron Pharma
Amgen
Astellas
Astex
Actinium Pharmaceuticals
Bellicum Pharmaceuticals
BioLineRx
Celator Pharmaceuticals
Cornerstone Pharmaceuticals
CTI BioPharma
Eli Lilly
Gamida Cell
GlaxoSmithKline
KaloBios Pharmaceuticals
Kiadis Pharma
Mirati Therapeutics
Onconova Therapeutics
Strategia Therapeutics
Sumitomo Dainippon Pharma
Sunesis Pharmaceuticals
Targazyme
TetraLogic Pharmaceuticals
Market driver
Rise in aging population
For a full, detailed list, view our report
Market challenge
Use of off-label drugs
For a full, detailed list, view our report
Market trend
Rise in public awareness
For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2019 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Product profile
REVLIMID
VIDAZA
Dacogen
Glivec/Gleevec
PART 04: Market research methodology
Research methodology
Economic indicators
PART 05: Introduction
Key market highlights
PART 06: Disease overview
Understanding the disease
Risk factors
Signs and symptoms
Pathophysiology
Types
Diagnosis
Epidemiology
Treatment
PART 07: Pipeline portfolio
Information on pipeline candidates
PART 08: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 09: Market segmentation by drug class
Alkylating agents
Cytotoxic antibiotics
Topoisomerase inhibitors
Others
PART 10: Market segmentation by route of administration
Oral
Parenteral
PART 11: Geographical Segmentation
Myelodysplastic syndrome market in EMEA
Myelodysplastic syndrome market in APAC
PART 12: Market drivers
Rise in aging population
Unmet medical needs
Use of diagnostic tools
PART 13: Impact of drivers
PART 14: Market challenges
Use of off-label drugs
Adverse effects of drugs
High cost of drugs
PART 15: Impact of drivers and challenges
PART 16: Market trends
Rise in public awareness
Patient assistance programs
Increase in R&D
Intense competition
PART 17: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors
PART 18: Key vendor analysis
Celgene
Novartis
Otsuka Holdings
PART 19: Appendix
List of abbreviations
PART 20: Explore Technavio
List Of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Myelodysplastic syndrome: Risk factors
Exhibit 03: Myelodysplastic syndrome: Signs and symptoms
Exhibit 04: History of myelodysplastic syndrome classification system
Exhibit 05: FAB classification system: Types of myelodysplastic syndrome
Exhibit 06: WHO classification system: Types of myelodysplastic syndrome
Exhibit 07: IPSS classification: Factors and score
Exhibit 08: IPSS-R classification: Cytogenetic score
Exhibit 09: IPSS-R classification: Score values
Exhibit 10: IPSS-R classification: Risk categories and scores
Exhibit 11: Diagnostic tests for myelodysplastic syndrome
Exhibit 12: Myelodysplastic syndrome: Global incidence based on age 2007-2011 (years)
Exhibit 13: Myelodysplastic syndrome: Incidence in US by race 2007-2011
Exhibit 14: Treatment options for myelodysplastic syndrome
Exhibit 15: Chemotherapeutic agents
Exhibit 16: Immunotherapy drugs
Exhibit 17: Supportive therapy for myelodysplastic syndrome
Exhibit 18: Drugs that received orphan designation for treatment of myelodysplastic syndrome
Exhibit 19: Myelodysplastic syndrome: Drug pipeline
Exhibit 20: Global myelodysplastic syndrome market ($ millions)
Exhibit 21: Five forces analysis
Exhibit 22: Global myelodysplastic syndrome market segmentation by drug class
Exhibit 23: Global myelodysplastic syndrome market segmentation by route of administration
Exhibit 24: Global myelodysplastic syndrome market segmentation by geography 2014
Exhibit 25: Myelodysplastic syndrome market in Americas 2014-2019 ($ millions)
Exhibit 26: Myelodysplastic syndrome market in EMEA 2014-2019 ($ millions)
Exhibit 27: Myelodysplastic syndrome market in APAC 2014-2019 ($ millions)
Exhibit 28: Global myelodysplastic syndrome market segmentation by geography 2014-2019 ($ millions)
Exhibit 29: Impact of drivers
Exhibit 30: Impact of drivers and challenges
Exhibit 31: Ranking of leading companies
Exhibit 32: Celgene: YoY growth and revenue of VIDAZA 2012-2014 ($ millions)
Exhibit 33: Celgene: YoY growth and revenue of REVLIMID 2012-2014 ($ billions)
Exhibit 34: Celgene: Key takeaways
Exhibit 35: Otsuka Holdings: Key takeaways
Exhibit 36: Novartis: Key takeaways
Exhibit 37: Celgene: Product segmentation by revenue 2014
Exhibit 38: Celgene: Product segmentation by revenue 2013 and 2014
Exhibit 39: Celgene: Geographical segmentation by revenue 2014
Exhibit 40: Novartis: Business segmentation by revenue 2014
Exhibit 41: Novartis: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 42: Novartis: Geographical segmentation by revenue 2014
Exhibit 43: Otsuka Holdings: Business segmentation by revenue 2014
Exhibit 44: Otsuka Holdings: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 45: Otsuka Holdings: Geographical segmentation by revenue 2014
